BIOCOMBiotech CSOs, CDMOs, CROs, lab specialists and AI developers gave an in-depth insight into next-generation antibody-based therapies to about 1,500 attendees at the 16th PEGS Europe in Barcelona. Several new formats are expected to enter the market in the next few years, promising to significantly reduce the side effects of CAR-Ts, bispecific antibodies, ADCs, etc. and improve their efficacy.
Tag Archive for: TME
TME Pharma (France/Germany) announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for NOX-A12 (olaptesed pegol), TME Pharma’s CXCL12 inhibitor, in combination with radiotherapy and bevacizumab for use in the treatment of the aggressive adult brain cancer glioblastoma.